Notably, despite an intermediate BRAF score of the BRAFG469A-mutated tumor, the BRAFT599dup-mutated tumor lay at the forefront of the cohort (Fig. 2f; Supplementary Table S4). This evidence concerns the gene BRAF and neoplasm.